论文信息 - Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura.

Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura.

We administered daclizumab, a humanized monoclonal anti-interleukin-2 receptor (IL-2R) antibody, to 11 patients with corticosteroid-refractory autoimmune thrombocytopenic purpura (AITP) every 2 weeks for five treatments. Of nine evaluable patients, one individual experienced a partial response. Lymphocyte phenotyping by flow cytometry indicated post-treatment binding of IL-2Ra by daclizumab in all patients. Mid-study serum soluble IL-2R levels in all patients increased 4-15 -fold over baseline values (p=0.004). Despite these measurable immunologic effects, blockade of the IL-2/IL-2R axis did not effectively abrogate the autoimmune response in this group of patients with corticosteroid-refractory AITP.

[1] M. Brown,et al. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab. , 2001, Clinical immunology.

[2] T. Waldmann,et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3] S. Light,et al. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. , 1998, Transplantation proceedings.

[4] Y. Aslan,et al. Plasma soluble interleukin‐2 receptor levels in patients with idiopathic thrombocytopenic purpura , 1998, American journal of hematology.

[5] J. Freedman,et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. , 1996, Blood.

[6] T. Taniguchi,et al. The IL-2 IL-2 receptor system: A current overview , 1993, Cell.

[7] P. Berchtold,et al. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. , 1993, Blood.

[8] J. Semple,et al. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. , 1991, Blood.